en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
6/2017
vol. 55
 
Share:
Share:
more
 
 
abstract:
Review paper

Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion

Brygida Kwiatkowska
,
Maria Majdan
,
Agnieszka Mastalerz-Migas
,
Maciej Niewada
,
Barbara Skrzydło-Radomańska
,
Artur Mamcarz

Reumatologia 2017; 55, 6: 290–297
Online publish date: 2017/12/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Pain is one of the most disabling symptoms of rheumatoid diseases. Patients with pain secondary to osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS) or gout require effective analgesic treatment, and the physician’s task is to select a drug that is best suited for an individual patient. The choice of pharmacotherapy should be based both on drug potency and clinical efficacy, and its safety profile, particularly in the elderly population, as the number of comorbidities (and hence the risk of treatment complications and drug interactions) rises with age. In cases involving a high risk of gastrointestinal complications or concerns about hepatotoxicity, with a low cardiovascular risk, the first-line nonsteroidal anti-inflammatory drugs to consider should be coxibs including etoricoxib.
keywords:

etoricoxib, coxibs, cyclooxygenase COX-2, pain treatment, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, gout







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.